INR 105.01
(-1.58%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 2.28 Billion INR | -79.95% |
2022 | 11.42 Billion INR | -4.82% |
2021 | 11.99 Billion INR | -1.24% |
2020 | 12.15 Billion INR | -1.17% |
2019 | 12.29 Billion INR | -6.19% |
2018 | 13.1 Billion INR | -10.83% |
2017 | 14.69 Billion INR | -8.25% |
2016 | 16.01 Billion INR | -5.61% |
2015 | 16.97 Billion INR | 3.65% |
2014 | 16.37 Billion INR | 1.49% |
2013 | 16.13 Billion INR | 6.1% |
2012 | 15.2 Billion INR | 9.12% |
2011 | 13.93 Billion INR | 20.08% |
2010 | 11.6 Billion INR | 40.49% |
2009 | 8.26 Billion INR | 38.36% |
2008 | 5.97 Billion INR | 26.4% |
2007 | 4.72 Billion INR | 22.27% |
2006 | 3.86 Billion INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 Q3 | - INR | -100.0% |
2023 FY | 2.28 Billion INR | -79.95% |
2023 Q2 | 10.68 Billion INR | 0.0% |
2023 Q4 | 2.28 Billion INR | 0.0% |
2023 Q1 | - INR | -100.0% |
2022 Q2 | 11.71 Billion INR | 0.0% |
2022 FY | 11.42 Billion INR | -4.82% |
2022 Q3 | - INR | -100.0% |
2022 Q4 | 11.42 Billion INR | 0.0% |
2022 Q1 | - INR | -100.0% |
2021 FY | 11.99 Billion INR | -1.24% |
2021 Q2 | 11.76 Billion INR | 0.0% |
2021 Q1 | - INR | -100.0% |
2021 Q3 | - INR | -100.0% |
2021 Q4 | 11.99 Billion INR | 0.0% |
2020 Q1 | - INR | -100.0% |
2020 FY | 12.15 Billion INR | -1.17% |
2020 Q3 | - INR | -100.0% |
2020 Q2 | 12.22 Billion INR | 0.0% |
2020 Q4 | 12.15 Billion INR | 0.0% |
2019 Q2 | 13.02 Billion INR | 0.0% |
2019 FY | 12.29 Billion INR | -6.19% |
2019 Q4 | 12.29 Billion INR | 0.0% |
2019 Q3 | - INR | -100.0% |
2018 Q4 | 13.1 Billion INR | 0.0% |
2018 FY | 13.1 Billion INR | -10.83% |
2017 FY | 14.69 Billion INR | -8.25% |
2016 FY | 16.01 Billion INR | -5.61% |
2015 FY | 16.97 Billion INR | 3.65% |
2014 FY | 16.37 Billion INR | 1.49% |
2013 FY | 16.13 Billion INR | 6.1% |
2012 Q4 | 15.2 Billion INR | 0.0% |
2012 FY | 15.2 Billion INR | 9.12% |
2012 Q2 | 30.23 Billion INR | 0.0% |
2011 FY | 13.93 Billion INR | 20.08% |
2010 FY | 11.6 Billion INR | 40.49% |
2009 FY | 8.26 Billion INR | 38.36% |
2008 FY | 5.97 Billion INR | 26.4% |
2007 FY | 4.72 Billion INR | 22.27% |
2006 FY | 3.86 Billion INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Sigachi Industries Limited | 2.53 Billion INR | 9.553% |
Ind-Swift Limited | 13.45 Billion INR | 82.982% |
Bajaj HealthCare Limited | 4.86 Billion INR | 52.966% |
Sakar Healthcare Limited | 1.26 Billion INR | -81.231% |
Aurobindo Pharma Limited | 152.2 Billion INR | 98.496% |
Innova Captab Limited | 4.89 Billion INR | 53.275% |
Divi's Laboratories Limited | 18.99 Billion INR | 87.944% |
AstraZeneca Pharma India Limited | 3.66 Billion INR | 37.465% |
Morepen Laboratories Limited | 4.45 Billion INR | 48.664% |
Mankind Pharma Limited | 23.87 Billion INR | 90.411% |
Sequent Scientific Limited | 8.27 Billion INR | 72.33% |
Wanbury Limited | 3.15 Billion INR | 27.446% |
Laurus Labs Limited | 42.71 Billion INR | 94.64% |
Nectar Lifesciences Limited | 11.21 Billion INR | 79.591% |
Glenmark Life Sciences Limited | 5.18 Billion INR | 55.81% |
Alembic Limited | 1.43 Billion INR | -59.867% |
Hikal Limited | 12.99 Billion INR | 82.382% |
Alembic Pharmaceuticals Limited | 16.27 Billion INR | 85.932% |
Neuland Laboratories Limited | 5.49 Billion INR | 58.363% |
J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 78.619% |
Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 96.484% |
IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 63.825% |
Themis Medicare Limited | 1.88 Billion INR | -21.295% |
RPG Life Sciences Limited | 1.38 Billion INR | -65.879% |
Zydus Lifesciences Limited | 71.79 Billion INR | 96.811% |
Lupin Limited | 96.23 Billion INR | 97.621% |
Amrutanjan Health Care Limited | 783.82 Million INR | -192.089% |
Wockhardt Limited | 39.87 Billion INR | 94.258% |
Vaishali Pharma Limited | 371.16 Million INR | -516.834% |
Aarti Pharmalabs Limited | 8.25 Billion INR | 72.251% |
Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -671.486% |
Jubilant Pharmova Limited | 61.27 Billion INR | 96.264% |
FDC Limited | 3.7 Billion INR | 38.276% |
Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 97.86% |
Kilitch Drugs (India) Limited | 643.88 Million INR | -255.571% |
Eris Lifesciences Limited | 38.26 Billion INR | 94.017% |
Venus Remedies Limited | 1.39 Billion INR | -64.378% |
ZIM Laboratories Limited | 2.08 Billion INR | -10.03% |
Bliss GVS Pharma Limited | 2.1 Billion INR | -8.564% |
Par Drugs and Chemicals Limited | 159.79 Million INR | -1332.785% |
Caplin Point Laboratories Limited | 3.5 Billion INR | 34.691% |
Shilpa Medicare Limited | 12.93 Billion INR | 82.297% |
Albert David Limited | 1.15 Billion INR | -99.065% |
Ajanta Pharma Limited | 10.71 Billion INR | 78.624% |
Hester Biosciences Limited | 3.59 Billion INR | 36.31% |
Suven Pharmaceuticals Limited | 2.03 Billion INR | -12.547% |
Solara Active Pharma Sciences Limited | 14.09 Billion INR | 83.753% |
Gufic Biosciences Limited | 5.59 Billion INR | 59.115% |
Windlas Biotech Limited | 1.76 Billion INR | -29.884% |
Procter & Gamble Health Limited | 2.56 Billion INR | 10.61% |
Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -32.939% |
Mangalam Drugs & Organics Limited | 1.97 Billion INR | -15.845% |
Granules India Limited | 22.95 Billion INR | 90.026% |
Aarti Drugs Limited | 11.5 Billion INR | 80.099% |
Bal Pharma Limited | 2.51 Billion INR | 8.833% |
Alkem Laboratories Limited | 48.6 Billion INR | 95.29% |
Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 98.753% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -113.063% |
Medicamen Biotech Limited | 940.36 Million INR | -143.465% |
Unichem Laboratories Limited | 8.06 Billion INR | 71.627% |
Bafna Pharmaceuticals Limited | 652.27 Million INR | -250.994% |
Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -692.752% |
Valiant Laboratories Limited | 1.05 Billion INR | -116.342% |
Orchid Pharma Limited | 3.84 Billion INR | 40.442% |
Medico Remedies Limited | 438.24 Million INR | -422.417% |
Ipca Laboratories Limited | 33.74 Billion INR | 93.215% |
Brooks Laboratories Limited | 248.6 Million INR | -820.938% |
Syncom Formulations (India) Limited | 1.16 Billion INR | -96.485% |
Piramal Enterprises Limited | 560.47 Billion INR | 99.592% |
Torrent Pharmaceuticals Limited | 82.05 Billion INR | 97.21% |
NATCO Pharma Limited | 10.53 Billion INR | 78.262% |
Suven Life Sciences Limited | 148.62 Million INR | -1440.469% |
Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 23.015% |
Strides Pharma Science Limited | 37.68 Billion INR | 93.924% |
Indoco Remedies Limited | 10.34 Billion INR | 77.863% |
Alpa Laboratories Limited | 307.12 Million INR | -645.457% |
Lasa Supergenerics Limited | 541.92 Million INR | -322.468% |
Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 41.189% |